文献速递中枢神经肿瘤放疗

新发胶质母细胞瘤患者在接受新型化放疗时代的剂量学失败模式

Dosimetric patterns of failure in the era of novel chemoradiotherapy in newly-diagnosed glioblastoma patients.
PubMed 文献 · Radiother Oncol · 2023-06-28

回顾109例新发胶质母细胞瘤患者,75例接受研究性化疗药物联合放化疗。替莫唑胺对照组失败模式在各进展时间点保持稳定(79%中心性、12%非中心性、9%两者兼有),而新型化疗组从初始到方案进展时非中心成分从16%增至29%(p=0.078)。失败模式与总生存或进展时间无关。

要点

  • 替莫唑胺对照组失败模式在各进展时间点保持稳定:79%中心性、12%非中心性、9%两者兼有。
  • 新型化疗组非中心成分从初始16%增至方案进展时29%(p=0.078),提示复发起源于中心区域。
  • 失败模式与总生存或进展时间无关。

核心结论

  • 接受新型化疗的患者的失败模式似乎受分析时间点影响,方案进展时较初始复发更趋于非中心性,提示复发起源于中心区域。
  • 加用依维莫司和伏立诺他似乎影响失败模式,尽管与替莫唑胺对照组生存结局相似。
  • 在涉及新型治疗药物的研究中,稳健且时机恰当的剂量学失败模式分析可能有助于评估新型药物的生物学特性。

研究设计与样本

  • 回顾性分析109例按2016年WHO分类新诊断的胶质母细胞瘤患者,均接受适形放疗联合同步及辅助替莫唑胺。
  • 其中75例还接受了研究性化疗药物(依维莫司、厄洛替尼或伏立诺他)。
  • 复发体积通过MRI对比增强定义。

主要发现

  • 替莫唑胺对照组失败模式在方案、初始和RANO进展时间点均不变:79%中心性、12%非中心性、9%两者兼有。
  • 新型化疗组从初始到方案进展时,非中心成分从16%增至29%(p=0.078)。
  • 失败模式与总生存或进展时间均无相关性。

关键数值与推荐

  • 失败模式按复发体积在95%剂量区域内的百分比表征。
  • 每位患者的方案、初始和RANO失败模式分类为中心性、非中心性或两者兼有。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patterns of failure (POF) may provide an alternative quantitative endpoint to overall survival for evaluation of novel chemoradiotherapy regimens with glioblastoma. MATERIALS AND METHODS: POF of 109 newly-diagnosed glioblastoma patients per 2016 WHO classification who received conformal radiotherapy with concomitant and adjuvant temozolomide were reviewed. Seventy-five of those patients also received an investigational chemotherapy agent (everolimus, erlotinib, or vorinostat). Recurrence volumes were defined with MRI contrast enhancement. POF at protocol (POFp), initial (POFi), and RANO (POFRANO) progression timepoints were characterized by the percentage of recurrence volume within the 95% dose region. POFp, POFi, and POFRANO of each patient were categorized (central, non-central, or both). RESULTS: POF of the temozolomide-only control cohort were unchanged (79% central, 12% non-central, and 9% both) across protocol, initial, and RANO progression timepoints. Unlike the temozolomide-only cohort, POF of the collective novel chemotherapy cohort appeared increasingly non-central when comparing POFi with POFp, with a non-central component increasing from 16% to 29% (p = 0.078). POF did not correlate with overall survival or time to progression. CONCLUSION: POF of patients receiving a novel chemotherapy appeared to be influenced by the timepoint of analysis and were increasingly non-central at protocol progression as compared with initial recurrence, suggesting that recurrence originates from the central region. Addition of everolimus and vorinostat appeared to influence POF, despite similar survival outcomes with the temozolomide-only control group. In studies dealing with novel therapeutic agents, robust and properly-timed dosimetric POF analysis may be helpful to evaluate biologic aspects of novel agents.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Seaberg MH, Kazda T, Youland RS, et al. Dosimetric patterns of failure in the era of novel chemoradiotherapy in newly-diagnosed glioblastoma patients. Radiother Oncol. 2023. PMID: 37385378. doi:10.1016/j.radonc.2023.109768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。